Consequences of patient access restrictions to branded oxycodone hydrochloride extended-release tablets on healthcare utilization and costs in US health plans

References

• American Academy of Pain Medicine. http://www.painmed.org/patientcenter/facts_on_pain.aspx#refer. Accessed August 13, 2013
   Google Scholar
• Relieving pain in America, a Blueprint for Transforming, Prevention, Care, Education and Research. Institute of Medicine Report from the Committee on Advancing Pain Research, The National Academies Press, Washington, DC. 2011
   Google Scholar
• Argoff C, Silvershein D. A comparison of long- and short-acting opioids for the treatment of chronic noncancer pain: tailoring therapy to meet patient needs. Mayo Clinic Proc 2009;84:602-12
   PubMed Web of Science ®Google Scholar
• Chou R, Fanciullo G, Fine P, et al. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain 2009;10:113-30
   PubMed Web of Science ®Google Scholar
• The United States Food and Drugs Administration News Release. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm367726.htm. Accessed April 29, 2014
   Google Scholar
• The United States Food and Drugs Administration. Goal of label changes: better prescribing, safer use of opioids. 2013. Washington DC, USA. http://www.fda.gov/forconsumers/consumerupdates/ucm367660.htm. Accessed April 30, 2014
   Google Scholar
• The United States Food and Drugs Administration. List of extended-release and long-acting opioid products required to have an opioid REMS. Washington DC, USA. http://www.fda.gov/drugs/drugsafety/Informationbydrugclass/ucm251735.htm. Accessed April 20, 2014
   Google Scholar
• United States Department of Justice. Drug Enforcement Agency. Drug scheduling. Washington DC, USA. http://www.justice.gov/dea/druginfo/ds.shtml. Accessed August 13, 2013
   Google Scholar
• Purdue Pharma. Oxycontin Full Prescribing Information 2014. Stamford, CT, USA. http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/022272s022lbl.pdf. Accessed April 20, 2014
   Google Scholar
• Academy of Managed Care Pharmacy, Common practice in formulary management systems. Academy of Managed Care Pharmacy, 2000. Alexandria, VA, USA. http://www.amcp.org/WorkArea/DownloadAsset.aspx?id=9274. Accessed April 28, 2014
   Google Scholar
• Leung M, Halpern M, West N. Pharmaceutical technology assessment: perspectives from payers. JMCP 2012;18:256-64
   PubMed Web of Science ®Google Scholar
• Seigfried R, Corbo T, Saltzberg M, et al. Deciding which drugs get onto the formulary: a value-based approach. Value Health 2013;16:901-6
   PubMedGoogle Scholar
• Delate T, Mager, DE, Sheth J. Clinical and financial outcomes associated with a proton pump inhibitor prior-authorization program in a Medicaid population. AJMC 2005;11:29-36
   Google Scholar
• Fischer M, Polinski J, Servi A, et al. Prior authorization for biologic disease-modifying antirheumatic drugs: a description of US Medicaid programs. Arthritis Rheum 2008;59:1611-7
   PubMed Web of Science ®Google Scholar
• Soumeria S, Zhang F, Ross-Degnan D, et al. Use of atypical antipsychotic drugs for schizophrenia in Maine Medicaid following a policy change. Health Affairs 2008;27:185-95
   Google Scholar
• Bazalo G, Weiss R, Joshi A. Impact of prior authorization for pregabalin on health plan drug expenditures. AJMC 2010;16:S154-9
   Google Scholar
• Margolis J, Cao Z, Onukwugha W, et al. Healthcare utilization and cost effects of prior authorization for pregabalin in commercial health plans. AJMC 2010;16:447-56
   Google Scholar
• Morden N, Zerzan J, Rue T, et al. Medicaid prior authorization and controlled-release oxycodone. Med Care 2008;46:573-80
   PubMed Web of Science ®Google Scholar
• Merchant S, Noe L, Howe A, et al. Budget impact analysis of tapentadol extended release for the treatment of moderate to severe chronic noncancer pain. Clin Therapeut 2013;35:359-72
   Google Scholar
• US Department of Health and Human Services. Food and Drug Adminstration. FDA actions on OxyContin Products 4/16/2013. FDA news release 2013. Washinton DC. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm348252.htm. Accessed September 26, 2013
   Google Scholar
• Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992;45:613-9
   PubMed Web of Science ®Google Scholar
• Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care 2005;43:1130-9
   PubMed Web of Science ®Google Scholar
• Davison AC, Hinkley DV. Bootstrap methods and their applications. Cambridge, England: Cambridge University Press, 1997
   Google Scholar
• McCullagh P, Nelder JA. Generalized Linear Models. 2nd edn. London: Chapman & Hall, 1989
   Google Scholar
• Table 2. Annual Statistical Report on the Social Security Disability Insurance Program, 2011. http://www.ssa.gov/policy/docs/statcomps/di_asr/2011/sect01a.html#table2. Accessed April 28, 2014
   Google Scholar
• Cantrill S, Brown M, Carlisle R, et al. Clinical policy: critical issues in the prescribing of opioids for adult patients in the emergency department. Ann Emerg Med 2012;60:499-525
   PubMed Web of Science ®Google Scholar
• Schultz D. Opioid use and abuse: a pain clinic perspective. Minn Med 2013;96:42-4
   PubMedGoogle Scholar
• Nelsen D. Opioids for the management of non-cancer pain. J Ark Med Soc 2013;109:252-3
   PubMedGoogle Scholar
• Noble M, Treadwell J, Tregear S, et al. Long-term opioid management for chronic noncancer pain. Cochrane Database Sytem Rev 2010;(1):CD006605
   Google Scholar
• Milhofer J. Finding a feasible solution. States employ different legislative strategies to curb misuse. Minn Med 2013;96:52-4
   PubMedGoogle Scholar
• Nosyk B, Anglin M, Brissette S, et al. A call for evidence-based medical treatment of opioid dependence in the United States and Canada. Health Aff 2013;32:1462-9
   PubMed Web of Science ®Google Scholar
• McPherson ML. Demystifying opioid conversion calculations: a guide for effective dosing. Bethesda, MD: American Society of Health-System Pharmacists, 2009
   Google Scholar
• Reissman D. What is the real cost of prior authorization? Drug Benefit Trends 2000;12:22-4
   Google Scholar
• Moeller D. Manage medical advances with automated prior authorization. Managed Executive 2009. http://managedhealthcareexecutive.modernmedicine.com/mhe/article/articleDetail.jsp?id=615491. Accessed November 20, 2013
   Google Scholar
• Balkrishnan R, Joish V, Bhosle MJ, et al. Prior authorization of newer insomnia medications in managed care: is it cost saving? J Clin Sleep Med 2007;3:393-8
   PubMedGoogle Scholar
• Frost FJ, Hurley JS, Petersen HV, et al. A comparison of two methods for estimating the health care costs of epilepsy. Epilepsia 2000;41:1020-6
   PubMed Web of Science ®Google Scholar
• Tunceli O, Wade R, Gu T, et al. Cost of diabetes: comparison of disease-attributable and matched cohort cost estimation methods. CMRO 2010;26:1827-34
   Google Scholar